Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Oligopro-Breast Study: Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study

NCT06925984 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT06925984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Oligopro-Breast Study: Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study
Lead sponsor
Jules Bordet Institute
Phase
Not applicable
Overall status
Recruiting
Start date
October 30, 2025
Completion date
May 1, 2030
Enrollment
48 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

oligoprogressive metastatic disease